Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch [Yahoo! Finance]
Mesoblast Limited - American Depositary Shares (MESO)
US:NASDAQ Investor Relations:
investorsmedia.mesoblast.com
Company Research
Source: Yahoo! Finance
® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGvHD). The funding is available at Mesoblast's option and will enable the Company to seamlessly implement its go-to-market commercial strategy. Mesoblast anticipates a decision prior to or on the FDA's Prescription Drug User Fee Act (PDUFA) goal date of January 7, 2025. Mesoblast Chief Executive Silviu Itescu said: “We appreciate the ongoing support from our major shareholder in ensuring that the Company is well capitalized for commercial product launch and can hit the ground running immediately following approval of RYONCIL by FDA.” Activities For Go to Market Strategy for RYONCIL in children with SR-aGvHD Hiring of select senior positions to build targeted commercial team has commenced. Key Pre-Launch Activities include: Market Access initiates payer outreach Medical provides education to payers Corporate leadership initiates engagement with Top 15 centers Reg
Show less
Read more
Impact Snapshot
Event Time:
MESO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MESO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MESO alerts
High impacting Mesoblast Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MESO
News
- Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings [Yahoo! Finance]Yahoo! Finance
- Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation MeetingsGlobeNewswire
- Mesoblast Limited (NASDAQ: MESO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $24.00 price target on the stock, up previously from $15.00.MarketBeat
- Mesoblast Limited (NASDAQ: MESO) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.MarketBeat
- Ryoncil® Commercial Launch Update and Product PipelineGlobeNewswire